Articles published by RevolKa Ltd.

RevolKa Reimagines Antibody Engineering with "RevoAb®"

Today 0:30 EDT

From RevolKa Ltd.

Via Business Wire

'RevoAb™', A New Service for Antibody Developability Engineering

September 09, 2025

From RevolKa Ltd.

Via Business Wire

RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)

June 30, 2025

From RevolKa Ltd.

Via Business Wire

RevolKa Ltd. Secures 210 million JPY (US$1.4 million) Series A Extension Funding to Advance Therapeutic Programs

May 19, 2025

From RevolKa Ltd.

Via Business Wire

RevolKa Ltd. Announces the Closing of a 250 Million JPY (US$1.7 Million) Series A Extension Funding to Accelerate Drug-Discovery Programs

August 29, 2024

From RevolKa Ltd.

Via Business Wire

RevolKa Signed Master Service Agreement with Daiichi Sankyo

May 27, 2024

From RevolKa Ltd.

Via Business Wire

La Jolla Institute for Immunology and RevolKa started a Research Collaboration

April 18, 2024

From RevolKa Ltd.

Via Business Wire

SEKISUI CHEMICAL CO., LTD. and RevolKa Signed a Contract Research Agreement

January 23, 2024

From RevolKa Ltd.

Via Business Wire

RevolKa Ltd.: Announcement of Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd.

June 23, 2023

From RevolKa Ltd.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.